274 related articles for article (PubMed ID: 38362962)
1. Research progress, challenges and perspectives of phospholipids metabolism in the LXR‑LPCAT3 signaling pathway and its relation to NAFLD (Review).
Wang J; Li J; Fu Y; Zhu Y; Lin L; Li Y
Int J Mol Med; 2024 Apr; 53(4):. PubMed ID: 38362962
[TBL] [Abstract][Full Text] [Related]
2. Phospholipid Remodeling in Physiology and Disease.
Wang B; Tontonoz P
Annu Rev Physiol; 2019 Feb; 81():165-188. PubMed ID: 30379616
[TBL] [Abstract][Full Text] [Related]
3. Identification of Hepatic Lysophosphatidylcholine Acyltransferase 3 as a Novel Target Gene Regulated by Peroxisome Proliferator-activated Receptor δ.
Singh AB; Liu J
J Biol Chem; 2017 Jan; 292(3):884-897. PubMed ID: 27913621
[TBL] [Abstract][Full Text] [Related]
4. LXRs regulate ER stress and inflammation through dynamic modulation of membrane phospholipid composition.
Rong X; Albert CJ; Hong C; Duerr MA; Chamberlain BT; Tarling EJ; Ito A; Gao J; Wang B; Edwards PA; Jung ME; Ford DA; Tontonoz P
Cell Metab; 2013 Nov; 18(5):685-97. PubMed ID: 24206663
[TBL] [Abstract][Full Text] [Related]
5. Deficiency in lysophosphatidylcholine acyltransferase 3 reduces plasma levels of lipids by reducing lipid absorption in mice.
Li Z; Jiang H; Ding T; Lou C; Bui HH; Kuo MS; Jiang XC
Gastroenterology; 2015 Nov; 149(6):1519-29. PubMed ID: 26226572
[TBL] [Abstract][Full Text] [Related]
6. Membrane phospholipid remodeling modulates nonalcoholic steatohepatitis progression by regulating mitochondrial homeostasis.
Tian Y; Jellinek MJ; Mehta K; Seok SM; Kuo SH; Lu W; Shi R; Lee R; Lau GW; Kemper JK; Zhang K; Ford DA; Wang B
Hepatology; 2024 Apr; 79(4):882-897. PubMed ID: 36999536
[TBL] [Abstract][Full Text] [Related]
7. Revisiting the Role of LXRs in PUFA Metabolism and Phospholipid Homeostasis.
Jalil A; Bourgeois T; Ménégaut L; Lagrost L; Thomas C; Masson D
Int J Mol Sci; 2019 Aug; 20(15):. PubMed ID: 31382500
[TBL] [Abstract][Full Text] [Related]
8. Substrate preferences of a lysophosphatidylcholine acyltransferase highlight its role in phospholipid remodeling.
Kazachkov M; Chen Q; Wang L; Zou J
Lipids; 2008 Oct; 43(10):895-902. PubMed ID: 18781350
[TBL] [Abstract][Full Text] [Related]
9. Free radical biology for medicine: learning from nonalcoholic fatty liver disease.
Serviddio G; Bellanti F; Vendemiale G
Free Radic Biol Med; 2013 Dec; 65():952-968. PubMed ID: 23994574
[TBL] [Abstract][Full Text] [Related]
10. ER phospholipid composition modulates lipogenesis during feeding and in obesity.
Rong X; Wang B; Palladino EN; de Aguiar Vallim TQ; Ford DA; Tontonoz P
J Clin Invest; 2017 Oct; 127(10):3640-3651. PubMed ID: 28846071
[TBL] [Abstract][Full Text] [Related]
11. Identification and characterization of a major liver lysophosphatidylcholine acyltransferase.
Zhao Y; Chen YQ; Bonacci TM; Bredt DS; Li S; Bensch WR; Moller DE; Kowala M; Konrad RJ; Cao G
J Biol Chem; 2008 Mar; 283(13):8258-65. PubMed ID: 18195019
[TBL] [Abstract][Full Text] [Related]
12. Research progress in the role and mechanism of LPCAT3 in metabolic related diseases and cancer.
Shao G; Qian Y; Lu L; Liu Y; Wu T; Ji G; Xu H
J Cancer; 2022; 13(8):2430-2439. PubMed ID: 35711841
[TBL] [Abstract][Full Text] [Related]
13. Lpcat3-dependent production of arachidonoyl phospholipids is a key determinant of triglyceride secretion.
Rong X; Wang B; Dunham MM; Hedde PN; Wong JS; Gratton E; Young SG; Ford DA; Tontonoz P
Elife; 2015 Mar; 4():. PubMed ID: 25806685
[TBL] [Abstract][Full Text] [Related]
14. Liver X receptors in lipid signalling and membrane homeostasis.
Wang B; Tontonoz P
Nat Rev Endocrinol; 2018 Aug; 14(8):452-463. PubMed ID: 29904174
[TBL] [Abstract][Full Text] [Related]
15. Liver x receptor regulates arachidonic acid distribution and eicosanoid release in human macrophages: a key role for lysophosphatidylcholine acyltransferase 3.
Ishibashi M; Varin A; Filomenko R; Lopez T; Athias A; Gambert P; Blache D; Thomas C; Gautier T; Lagrost L; Masson D
Arterioscler Thromb Vasc Biol; 2013 Jun; 33(6):1171-9. PubMed ID: 23580142
[TBL] [Abstract][Full Text] [Related]
16. n-3 Polyunsaturated fatty acids for the management of alcoholic liver disease: A critical review.
Wang M; Ma LJ; Yang Y; Xiao Z; Wan JB
Crit Rev Food Sci Nutr; 2019; 59(sup1):S116-S129. PubMed ID: 30580553
[TBL] [Abstract][Full Text] [Related]
17. Ursodeoxycholyl Lysophosphatidylethanolamide modifies aberrant lipid profiles in NAFLD.
Pathil A; Liebisch G; Okun JG; Chamulitrat W; Schmitz G; Stremmel W
Eur J Clin Invest; 2015 Sep; 45(9):925-31. PubMed ID: 26108973
[TBL] [Abstract][Full Text] [Related]
18. Lipidomic analysis of human primary hepatocytes following LXR activation with GW3965 identifies AGXT2L1 as a main target associated to changes in phosphatidylethanolamine.
Santinha D; Klopot A; Marques I; Ellis E; Jorns C; Johansson H; Melo T; Antonson P; Jakobsson T; Félix V; Gustafsson JÅ; Domingues MR; Mode A; Helguero LA
J Steroid Biochem Mol Biol; 2020 Apr; 198():105558. PubMed ID: 31783151
[TBL] [Abstract][Full Text] [Related]
19. Biological mechanisms and related natural modulators of liver X receptor in nonalcoholic fatty liver disease.
Ni M; Zhang B; Zhao J; Feng Q; Peng J; Hu Y; Zhao Y
Biomed Pharmacother; 2019 May; 113():108778. PubMed ID: 30897538
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of LXR signaling by SULT2B1b promotes liver regeneration after partial hepatectomy in mouse models of nonalcoholic fatty liver disease.
Zhang X; Xu Y; Bai Q; Li X; Han J; Hou Y; Ji Y; Zhang Z
Am J Physiol Gastrointest Liver Physiol; 2020 Jul; 319(1):G87-G96. PubMed ID: 32475129
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
